
Partnership advances AI-driven R&D collaboration
Insilico Medicine has achieved the early drug discovery milestone in its multi-year AI-driven drug discovery collaboration with pharmaceutical group Servier. Under the collaboration, the two companies initiated two distinct R&D programmes for oncology on challenging targets leveraging Insilico’s proprietary end-to-end AI platform, Pharma.AI. Target nominations have been… Read More














